Taken together, we demonstrate here that a combination therapy simultaneously targeting an epigenetic mediator (OCT4) and an epigenetic modulator (AKT), can have significantly improved efficacies over single treatment in suppressing the propagation of CSCs as well as the entire bulk of differentiated cancer cells. Here, AKT1 is linked to cancer.